Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04271384

Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Stage I Clinical Trial

Official title:
Stereotactic Ablative Radiotherapy in Combination With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer: a Phase 2 Study

Clinical Trial Summary

Stage 1 non-small cell lung cancer (NSCLC) carries up to 30% chance of relapse in 5 years. This a phase 2 study that aims to determine the pathological complete response of the combination of stereotactic ablative radiotherapy (SABR) plus nivolumab as neoadjuvant treatment in early-stage non-small cell lung cancer. The patients will receive standard SABR + nivolumab at a dose of 360 mg every 21 days for 3 doses. The patient will undergo surgery 10 weeks after the last radiotherapy dose.

Clinical Trial Description

Stage 1 non-small cell lung cancer (NSCLC) carries up to 30% chance of relapse in 5 years. Surgery is standard-of-care for this population. For patients who are not candidate for surgery, stereotactic ablative radiotherapy (SABR) is standard, with good local control but locoregional and distant failure. The use of preoperative SABR leads to a pathological complete response rate (pCR) of 60%. Anti-PD-1 has the ability to provoke a pCR in around 20% of patients as a single agent. Moreover, it has synergic activity with radiotherapy. This a phase 2 study that aims to determine the pathological complete response of the combination of stereotactic ablative radiotherapy plus nivolumab as neoadjuvant treatment in early-stage non-small cell lung cancer. The patients will receive standard SABR, given either as 3, 5 or 8 fractions (depending on tumor size and location) + nivolumab at a dose of 360 mg every 21 days for 3 doses. The patient will undergo surgery 10 weeks after the last radiotherapy dose. We will measure translational biomarkers associated with either pCR or resistance to therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04271384
Study type Interventional
Source Hospital Israelita Albert Einstein
Contact
Status Completed
Phase Phase 2
Start date February 12, 2020
Completion date November 15, 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05451173 - Combining ICI With SBRT or HypoFrx-RT for ES NSCLC Phase 1/Phase 2
Active, not recruiting NCT03603002 - Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer N/A
Completed NCT04342377 - The Canada Lymph Node Score Project: A Crossover Trial Phase 3
Recruiting NCT05097417 - Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer N/A
Recruiting NCT06341387 - Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer
Completed NCT01991418 - Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC) N/A
Completed NCT03216551 - Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC (ECTOP-1003)
Recruiting NCT03172156 - ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS N/A
Withdrawn NCT03431415 - Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer N/A
Recruiting NCT04716946 - Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy Phase 2
Withdrawn NCT03029871 - Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer Phase 1
Active, not recruiting NCT06180239 - Segmentectomy vs Lobectomy
Active, not recruiting NCT03383302 - SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects Phase 1/Phase 2
Recruiting NCT02622581 - Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Not yet recruiting NCT02011997 - Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Phase 3
Recruiting NCT05453721 - Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane（IMPLANE-0529） N/A
Active, not recruiting NCT01795521 - LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC Phase 2
Recruiting NCT04944173 - SCION: SABR and Checkpoint Inhibition Of NSCLC Phase 2
Recruiting NCT04585477 - Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) Phase 2